Sunday 18 October 2026
Export CYPH’s income statement to Excel — free account
Cypherpunk Technologies Inc.
CYPH Healthcare Biotechnology
In the quarter to June 2026, EPS grew 152.5% and free cash flow grew 15.5%, each against the same quarter a year earlier.
2.57
0.45
−14.90%
Follow CYPH
Cypherpunk Technologies Inc. (CYPH) P/E ratio
As of 16 October 2026, Cypherpunk Technologies Inc. (CYPH) trades at a P/E ratio of 4.4×. Over the past ten years it has ranged from 0.0× (June 2026) to 17.0× (January 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 17.0×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TTRX Turn Therapeutics Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| IRD Opus Genetics, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| AGEN Agenus Inc. compare | 2.3× |
| CYPH Cypherpunk Technologies Inc. | 4.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)